• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

‘Chorioamnionitis or Triple I’ – How Valid is the NICHD Guideline for the Diagnosis of Intrauterine Infection?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • In 2015, NICHD recommended
    • Replace ‘chorioamnionitis’ with ‘Triple I’
      • Intrauterine Inflammation or Infection or both
      • Antibiotics given only for those meeting ‘Triple I’ criteria
      • Isolated fever would not necessarily be treated
    • Samsiya et al. (Obstetrics & Gynecology, 2019) sought to assess the diagnostic validity of the ‘Triple I’ approach for the intrauterine infection
      • Authors additionally measured rates of adverse outcomes in a cohort of febrile intrapartum women

METHODS:

  • Retrospective cohort study
  • Women included with the following
    • ≥24 weeks gestation
    • Temperature ≥100.4°F (38.0°C) during labor or within 1 hour postpartum
    • Available blood culture data
  • Fever defined as
    • Single temperature ≥102.2°F (39.0°C) or
    • ≥100.4°F (38.0°C) but <102.2°F (39.0°C) on two measurements 45 minutes apart
  • Two analysis groups were defined
    • Suspected triple I
      • Documented fever with clinical signs of infection
    • Isolated maternal fever
      • At least one temperature ≥100.4°F (38.0°C) in women who did not meet criteria for suspected triple I
    • NICHD test characteristics ability to predict suspected triple I was assessed
      • Confirmed triple I: Suspected triple I with placental pathology confirmation
    • Adverse clinical infectious outcome
      • Composite of maternal and neonatal adverse infectious outcomes

RESULTS:

  • 339 women
    • 212 with suspected triple I | 127 with isolated maternal fever
  • Incidence of adverse clinical infectious outcomes (P=.50)
    • Women with suspected triple I: 11.8%
    • Women with isolated maternal fever: 9.5%
  • Performance characteristics of suspected triple I for confirmed triple I
    • Sensitivity: of 71.4% (95% CI 61.4–80.1%)
    • Specificity: 40.5% (95% CI 33.6–47.8%)
  • Performance characteristics for predicting adverse clinical infectious outcomes
    • Sensitivity: 67.6% (95% CI 50.2–82.0%)
    • Specificity: 38.1% (95% CI 32.6–43.8%)

CONCLUSION:

  • NICHD criteria may miss a significant proportion of laboring febrile women at risk for adverse infectious outcomes
  • NICHD guideline had low sensitivity and specificity
  • Women with isolated fever were at risk for adverse infectious outcomes
  • The authors state

Following the publication of the triple I criteria, the American College of Obstetricians and Gynecologists issued a statement recommending consideration of treatment of women who fall under the umbrella of isolated maternal fever as defined by the NICHD, and our study supports this recommendation

Learn More – Primary Sources:

Diagnostic Validity of the Proposed Eunice Kennedy Shriver National Institute of Child Health and Human Development Criteria for Intrauterine Inflammation or Infection

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More »

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Chorioamnionitis: ACOG Committee Opinion on Diagnosis and Management
Does Intrapartum Fever Really Predict Neonatal Sepsis?
Updated Guidance on GBS Screening and Prophylaxis

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site